Federal Register / Vol. 82, No. 165 / Monday, August 28, 2017 / Notices 40775 

There will be a final report that is 

thematically organized and describes 

key findings and strategic 

recommendations for Region VIII 

OASH/OWH to consider supporting 

future evidence-based program 

development and implementation, 

policy recommendations, and future 

research. 

Likely Respondents: Data for this 

assessment will be collected through 

three mechanisms—a survey of women 

living in the assessment geography, 

focus groups with a cross-section of 

women and other key groups living in 

the assessment geography, key leaders 

and stakeholders across a variety of 

governmental and non-governmental 

sectors. 

The total annual burden hours 

estimated for this ICR are summarized 

in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

Community Survey .......................................................................................... 500 1 15/60 125 

Focus Groups .................................................................................................. 240 1 90/60 360 

Interviews ......................................................................................................... 40 1 60/60 40 

Total .......................................................................................................... 780 1 40.4/60 525 

Terry S. Clark, 

Asst Information Collection Clearance 

Officer. 

[FR Doc. 2017–18117 Filed 8–25–17; 8:45 am] 

BILLING CODE 4150–33–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Allergy and 

Infectious Diseases; Notice of Closed 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute of 

Allergy and Infectious Diseases Special 

Emphasis Panel NIAID Peer Review Meeting. 

Date: September 20–21, 2017. 

Time: 12:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 5601 

Fishers Lane, Rockville, MD 20892, 

(Telephone Conference Call). 

Contact Person: Kelly Y. Poe, Ph.D., 

Scientific Review Program, Division of 

Extramural Activities, Room 3F40B, National 

Institutes of Health, NIAID, 5601 Fishers 

Lane, MSC 9823, Bethesda, MD 20892–9823, 

(240) 669–5036, poeky@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.855, Allergy, Immunology, 

and Transplantation Research; 93.856, 

Microbiology and Infectious Diseases 

Research, National Institutes of Health, HHS) 

Dated: August 22, 2017. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–18121 Filed 8–25–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The inventions listed below 

are owned by an agency of the U.S. 

Government and are available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Chris Kornak, 240–627–3705, 

Chris.Kornak@nih.gov. Licensing 

information and copies of the U.S. 

patent applications listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

HIV Targets CD62L on Central Memory 

T Cells Through Viral Envelope 

Glycans for Adhesion and Induces 

Selectin Shedding for Viral Release 

Description of Technology 

Despite the success of anti-retroviral 

therapy in controlling HIV in infected 

individuals, treatment is less effective at 

eliminating HIV viral reservoirs. The 

nature of HIV reservoirs and the factors 

controlling their size and release are a 

major research focus for achieving a 

cure for HIV/AIDS. 

NIAID researchers have identified Lselectin/CD62L as a new target for 

treating HIV by inhibiting viral release 

from infected cells. They found that 

shedding of CD62L on T cells is 

required for the efficient release of HIV 

virus from infected cells. Further, they 

have shown that inhibition of CD62L 

shedding dramatically reduced HIV–1 

infection and viral release from both 

viremic and aviremic CD4+ T cells. 

Therefore, inhibitors for CD62L 

sheddase can function as an anti-HIV 

treatment that may be effective alone or 

in combination with existing 

therapeutics. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• New target for HIV therapeutic 

development. 


asabaliauskas on DSKBBXCHB2PROD with NOTICES